- Home
- ONFO vs CYCN Comparison
ONFO vs CYCN Comparison
Compare ONFO & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONFO
- CYCN
- Stock Information
- Founded
- ONFO 2018
- CYCN 2018
- Country
- ONFO United States
- CYCN United States
- Employees
- ONFO N/A
- CYCN N/A
- Industry
- ONFO Computer Software: Programming Data Processing
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- ONFO Technology
- CYCN Health Care
- Exchange
- ONFO Nasdaq
- CYCN Nasdaq
- Market Cap
- ONFO 5.8M
- CYCN 6.5M
- IPO Year
- ONFO 2022
- CYCN N/A
- Fundamental
- Price
- ONFO $1.04
- CYCN $3.04
- Analyst Decision
- ONFO
- CYCN
- Analyst Count
- ONFO 0
- CYCN 0
- Target Price
- ONFO N/A
- CYCN N/A
- AVG Volume (30 Days)
- ONFO 8.4K
- CYCN 16.1K
- Earning Date
- ONFO 05-16-2025
- CYCN 05-23-2025
- Dividend Yield
- ONFO N/A
- CYCN N/A
- EPS Growth
- ONFO N/A
- CYCN N/A
- EPS
- ONFO N/A
- CYCN N/A
- Revenue
- ONFO $9,087,118.00
- CYCN $2,081,000.00
- Revenue This Year
- ONFO N/A
- CYCN N/A
- Revenue Next Year
- ONFO N/A
- CYCN N/A
- P/E Ratio
- ONFO N/A
- CYCN N/A
- Revenue Growth
- ONFO 50.04
- CYCN N/A
- 52 Week Low
- ONFO $0.49
- CYCN $1.27
- 52 Week High
- ONFO $1.88
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- ONFO 45.70
- CYCN 50.15
- Support Level
- ONFO $1.01
- CYCN $2.83
- Resistance Level
- ONFO $1.10
- CYCN $3.34
- Average True Range (ATR)
- ONFO 0.02
- CYCN 0.32
- MACD
- ONFO -0.00
- CYCN -0.04
- Stochastic Oscillator
- ONFO 40.00
- CYCN 22.68
About ONFO Onfolio Holdings Inc.
Onfolio Holdings Inc actively manages small online businesses that operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by existing teams or have management teams largely in place.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.